Healthcare provider profile · identity verified

Sumitha Atluri, MD

Internal Medicine · IRVING, TX · NPI 1265513923

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	428	136
Levothyroxine Sodium	Levothyroxine Sodium	257	71
Losartan Potassium	Losartan Potassium	239	75
Rosuvastatin Calcium	Rosuvastatin Calcium	227	82
Amlodipine Besylate	Amlodipine Besylate	226	70
Mounjaro	Tirzepatide	146	29
Montelukast Sodium	Montelukast Sodium	141	45
Lisinopril	Lisinopril	131	35
Pantoprazole Sodium	Pantoprazole Sodium	129	54
Gabapentin	Gabapentin	125	45
Metformin Hcl	Metformin Hcl	114	35
Carvedilol	Carvedilol	112	34
Ozempic	Semaglutide	107	26
Escitalopram Oxalate	Escitalopram Oxalate	101	32
Metoprolol Succinate	Metoprolol Succinate	94	29
Metformin Hcl Er	Metformin Hcl	92	41
Trazodone Hcl	Trazodone Hcl	91	34
Methylprednisolone	Methylprednisolone	89	71
Azelastine Hcl	Azelastine Hcl	80	43
Omeprazole	Omeprazole	79	28
Jardiance	Empagliflozin	78	29
Tizanidine Hcl	Tizanidine Hcl	70	30
Zolpidem Tartrate	Zolpidem Tartrate	69	suppressed
Celecoxib	Celecoxib	66	29
Potassium Chloride	Potassium Chloride	66	27
Famotidine	Famotidine	65	23
Azithromycin	Azithromycin	64	54
Furosemide	Furosemide	64	26
Simvastatin	Simvastatin	59	15
Synthroid	Levothyroxine Sodium	58	16
Albuterol Sulfate Hfa	Albuterol Sulfate	55	28
Allopurinol	Allopurinol	54	16
Fluticasone Propionate	Fluticasone Propionate	52	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	52	18
Pregabalin	Pregabalin	52	17
Spironolactone	Spironolactone	51	17
Alendronate Sodium	Alendronate Sodium	49	19
Ezetimibe	Ezetimibe	49	19
Sertraline Hcl	Sertraline Hcl	43	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	43	28
Chlorthalidone	Chlorthalidone	41	16
Tamsulosin Hcl	Tamsulosin Hcl	39	15
Duloxetine Hcl	Duloxetine Hcl	38	15
Baclofen	Baclofen	36	suppressed
Ondansetron Odt	Ondansetron	36	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	34	13
Linzess	Linaclotide	34	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	suppressed
Alprazolam	Alprazolam	32	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Tramadol Hcl	Tramadol Hcl	29	16
Valacyclovir	Valacyclovir Hcl	29	19
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Eliquis	Apixaban	27	suppressed
Ketoconazole	Ketoconazole	27	16
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	27	12
Methocarbamol	Methocarbamol	27	11
Trulicity	Dulaglutide	27	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	17
Prednisone	Prednisone	26	23
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Finasteride	Finasteride	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	23
Clonazepam	Clonazepam	24	suppressed
Acyclovir	Acyclovir	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	16
Rybelsus	Semaglutide	23	suppressed
Glipizide	Glipizide	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Atenolol	Atenolol	21	suppressed
Fluconazole	Fluconazole	21	12
Nystatin	Nystatin	21	suppressed
Hydrocortisone	Hydrocortisone	20	suppressed
Meloxicam	Meloxicam	20	13
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Novolog Flexpen	Insulin Aspart	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	18	18
Farxiga	Dapagliflozin Propanediol	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	13
Glimepiride	Glimepiride	17	suppressed
Loperamide	Loperamide Hcl	17	suppressed
Rizatriptan	Rizatriptan Benzoate	17	suppressed
Valsartan	Valsartan	17	suppressed
Cephalexin	Cephalexin	16	14
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Solifenacin Succinate	Solifenacin Succinate	16	suppressed
Veozah	Fezolinetant	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Hydrochlorothiazide	Hydrochlorothiazide	14	suppressed
Olanzapine	Olanzapine	14	suppressed
Vascepa	Icosapent Ethyl	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	suppressed
Albuterol Sulfate	Albuterol Sulfate	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	suppressed
Estradiol	Estradiol	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Zenpep	Lipase/Protease/Amylase	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error